Searchable abstracts of presentations at key conferences in endocrinology

ea0011p500 | Endocrine tumours and neoplasia | ECE2006

Development of dopamine agonist resistance and progression from microadenoma to macroadenoma in two women with hyperprolactinaemia

McCall D , Hunter SJ , Cooke RS , Herron B , Sheridan B , Atkinson AB

Dopamine agonist therapy is an effective long-term treatment in >90% of patients with hyperprolactinaemia, controlling both prolactin secretion and tumour growth. We describe the unusual late emergence of resistance to high-dose dopamine agonist treatment in two recent female patients. Both women presented with secondary amenorrhoea, were shown to have high prolactin levels and a pituitary microadenoma. Each had an excellent initial response to bromocriptine but years late...

ea0007p212 | Steroids | BES2004

Role of PPAR-gamma receptor agonist therapy in two patients with newly diagnosed pituitary-dependent Cushing's syndrome

Hull S , Sheridan B , Atkinson A

Existing treatments for pituitary-dependent Cushing's Syndrome include pituitary or adrenal surgery, pituitary irradiation and medical therapy. Pituitary microsurgery is the usual therapy of first choice but is not always successful in achieving early apparent remission and is associated with significant late relapses. An effective drug therapy for humans would be a major advance as there is significant morbidity and mortality in Cushing's Syndrome. Recent elegant in vitro and...

ea0003p38 | Clinical Case Reports | BES2002

Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage. A reason for cautious optimism ?

Harding J , Sheridan B , Atkinson A

A 45-year-old lady presented with a 12-month history of blurred vision. Visual assessment revealed a bitemporal hemianopia and CT scan demonstrated a large pituitary tumour with lateral and suprasellar extension. A GTT showed her growth hormone was raised basally at 7.5 milliunits per litre and incompletely suppressed to 5.7 milliunits per litre confirming acromegaly. Transsphenoidal hypophysectomy was performed. Histology confirmed a somatoptroph adenoma. Post operatively she...

ea0003p39 | Clinical Case Reports | BES2002

Hyperprolactinaemia in a patient taking the herbal remedy Agnus Castus

Harding J , Sheridan B , Atkinson A

A 34-year-old woman, presented to her General Practitioner with hot flushes. Investigations showed her to have a normal LH, FSH, free T4 and TSH. Her prolactin was elevated at 1110 milliunits per litre (NR <350 ). She had a normal menarche age 14 and had regular 28 day menstrual cycles. Before the onset of the hot flushes she had started to take agnus castus, a herbal remedy said to help symptoms of premenstrual tension.Whilst she continued to take ...

ea0003p28 | Clinical Case Reports | BES2002

Cushing's syndrome of indeterminate origin. Sucessful treatment of a liver abscess after therapy with a block and replacement medical regimen

Harding J , Kennedy A , Sheridan B , Atkinson A

A 67 yr old lady was admitted with left ventricular failure, angina, and atrial fibrillation. She was hypokalaemic (2.5mmol/l). There was a 3 year history of hypertension and a new diagnosis of diabetes mellitus. There was a recent history of weight gain, muscle weakness, bruising and facial puffiness. On examination she appeared cushingoid. A 24 hour urine for free cortisol was 1438nmol\/24h (normal<350). A basal 0800h serum cortisol was 1061nmol/l. After low dose dexameth...

ea0011p741 | Steroids | ECE2006

Can the 250mcg synacthen test be used to screen for primary hyperaldosteronism?

Mullan K , Leslie H , Sheridan B , Atkinson AB

Primary hyperaldosteronism secondary to bilateral adrenal hyperplasia (BAH) bears striking similarities pathophysiologically to essential hypertension. During stimulation studies to elucidate possible aberrant aldosterone responses in BAH we measured the aldosterone response to 250mcg iv synacthen after 30 and 60 minutes in 7 patients with BAH and in 20 healthy controls. Patients had diuretics withheld for at least 4 weeks and betablockers and calcium channel blockers withheld...

ea0007p292 | Clinical case reports | BES2004

A case of severe congenital adrenal hyperplasia treated successfully with laparoscopic bilateral adrenalectomy

Mullan K , Russell C , Dolan S , Sheridan B , Atkinson A

A 14 year old girl was referred with a diagnosis, made at birth, of congenital adrenal hyperplasia. She had undergone clitoral reduction and vulvovaginoplasty at age 2. Her height had been on 10th-25 th centile, and, at presentation to us, she was taking prednisolone (7.5milligrams in divided doses) and fludrocortisone 0.05 milligrams. At age 14 her height dropped to the 3 rd centile. She was hirsute, obese and had abdominal striae. A variety of steroid regimes only led to an ...

ea0003p273 | Steroids | BES2002

Long-term overall success after transsphenoidal surgery for Cushing's disease: Time for a reappraisal of therapy?

Kennedy A , Wiggam M , Hadden D , Mccance D , Sheridan B , Atkinson A

There have been few reports of long term remission rates after transsphenoidal surgery for Cushing's disease which incorporate both initial failure rates and later relapse rates. We have studied this in patients diagnosed and treated between 1979 and 2000. An early post-operative 0800h serum cortisol was measured 24h after the last dose of hydrocortisone, in addition to a low dose dexamethasone suppression test. Of the initial 63 patients, 18 did not achieve remission after su...

ea0007oc29 | Endocrine tumours | BES2004

Clinical experience of intra-arterial calcium gluconate-stimulated hepatic venous sampling in the localisation of insulinomas

Kassim S , Ellis P , Atkinson A , Hunter S , Sheridan B , Russell C , McCance D

Objective: to evaluate the role of pre-operative insulinoma localisation using selective intra-arterial calcium gluconate stimulated hepatic venous sampling.Method: Calcium gluconate (0.025 milliEquivalents Ca per kilogram) is used as a secretagogue to promote insulin secretion. Simultaneous catheterisation of right hepatic vein and pancreatic arterial supply were performed. The secretagogue was infused into the gastroduodenal, splenic, common hepatic an...

ea0005p149 | Endocrine Tumours and Neoplasia | BES2003

Usefulness of growth hormone response to a test dose of subcutaneous octreotide in predicting longer-term response to the drug. Poor responses predict the need for adjuvant therapy to achieve 'safe' growth hormone levels

Lindsay J , McConnell E , Hunter S , McCance D , Sheridan B , Atkinson A

From a group of 41 patients with acromegaly, the majority of whom had pituitary surgery as primary therapy, we have compared growth hormone responses to a test dose of octreotide across 8 hours with a 3 year random growth hormone in 22 patients who at the 3 year assessment were receiving at least 600mcg octreotide daily subcutaneously or 20mg LAR monthly intramuscularly and in 2 other patients who had achieved 3 year GH of <5 mU/l on smaller doses. Seven patients had a basa...